Superior Efficacy of Victoza Compared to Januvia in the Treatment of Type 2 Diabetes


Novo Nordisk’s new diabetes drug Victoza proved more effective than Merck & Co’s Januvia in a head-to-head study published, in the Lancet.
The 26-week trial showed that Victoza produced significantly greater reductions in HbA1C, fasting plasma glucose and body weight than Januvia, with similar or better overall treatment satisfaction.
According to a Novo Nordisk announcement significantly more patients achieved the HbA1c targets of <7·0% (American Diabetes Association [ADA]). Nearly twice as many study participants on Victoza reached the ADA goal compared to the Januvia group.

0 0 vote
Article Rating
Notify of
Inline Feedbacks
View all comments
Copyright © 2009-2020 Diabetes Media Foundation, All Rights Reserved.
ASweetLife™ is a trademark of the Diabetes Media Foundation, All Rights Reserved.
DMCA Compliant
Would love your thoughts, please comment.x